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Abstract The translation initiation factor eIF4A is cleaved
within mammalian cells infected by foot-and-mouth disease virus
(FMDV). The FMDV 3C protease cleaves eIF4AI (between
residues E143 and V144), but not the closely related eIF4AII.
Modification of eIF4AI, to produce a sequence identical to
eIF4AII around the cleavage site, blocked proteolysis. Alignment
of mammalian eIF4AI onto the three-dimensional structure of
yeast eIF4A located the scissile bond within an exposed, flexible
portion of the molecule. The N- and C-terminal cleavage
products of eIF4AI generated by FMDV 3C dissociate. Cleavage
of eIF4AI by FMDV 3C is thus expected to inactivate
it. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The translation initiation factor complex eIF4F has a cen-
tral role in the initiation of protein synthesis in mammalian
cells (reviewed in [1]) and comprises eIF4E, eIF4A and
eIF4G. eIF4E binds to the 5P-cap-structure (m7GpppNT) of
mRNAs while eIF4A is the prototypic member of the DEAD
box family of RNA helicases [2]. eIF4G is a sca¡old protein
that binds not only eIF4E and eIF4A but also eIF3 (associ-
ated with the ribosome), the poly(A) binding protein and
Mnk-1 (an eIF4E kinase). Thus eIF4G bridges between the
mRNA and the small ribosomal subunit [1].
The picornavirus family comprises many important human
and animal pathogens including poliovirus (PV), foot-and-
mouth disease virus (FMDV) and encephalomyocarditis virus
(EMCV). Picornaviruses have a positive sense RNA genome
of about 8 kb that acts like a mRNA. These RNAs are un-
capped and have long (600^1300 nucleotides (nt)) 5P untrans-
lated regions that include internal ribosome entry site (IRES)
elements (ca. 450 nt) which direct translation initiation on the
picornavirus RNA (see [3^5]). Within cells infected by FMDV
and PV, rapid inhibition of cellular cap-dependent protein
synthesis occurs following virus-induced cleavage of eIF4G.
Picornavirus IRES elements direct translation initiation using
just the central and C-terminal domains of eIF4G, which has
binding sites for eIF4A and eIF3 [6^8]. Cleavage of eIF4G is
induced by the PV 2A protease [9] and by the unrelated
FMDV leader (L) and 3C proteases [10^12] at distinct sites.
We have shown that eIF4A (ca. 48 kDa) is also cleaved in
FMDV-infected cells to produce a stable C-terminal product
(33 kDa) and that this cleavage requires the FMDV 3C pro-
tease [12]. The progressive cleavage of eIF4A, from about 3 h
post-infection, is co-incident with the decline in the level of
viral RNA translation [12]. Two cytoplasmic forms of mam-
malian eIF4A have been identi¢ed, termed eIF4AI and eI-
F4AII, that are 91% identical and appear to be functionally
interchangeable [13]. eIF4A is the most abundant of the trans-
lation initiation factors [14], it exists within the eIF4F com-
plex and also free within the cytoplasm [13]. Capped mRNAs
and picornavirus IRES-containing RNAs require eIF4A to
achieve e⁄cient 48S initiation complex formation in vitro
[6,15] and dominant negative mutants of eIF4A block both
modes of translation initiation [16,17]. eIF4A has ATP-depen-
dent RNA helicase activity which is stimulated by eIF4B [18].
The three-dimensional (3D) structure of yeast eIF4A has been
determined [19^21].
No cleavage of eIF4A occurs in PV- or EMCV-infected
cells [12,22] and currently it appears unique to FMDV-in-
fected cells. We now show that eIF4AI (but not eIF4AII) is
cleaved directly by FMDV 3C in vitro and identify the scissile
bond. The cleavage separates critical regions within eIF4AI
required for helicase activity.
2. Materials and methods
2.1. Expression plasmids for eIF4AI, eIF4AII and derivatives
The plasmid pcDNA3.1/GS4AI (Invitrogen) contains the human
eIF4AI coding sequence with C-terminal hexa-His and V5-epitope
tags under the control of CMV and T7 promoters. Derivatives of
the eIF4AI cDNA lacking sequences encoding the N-terminus of
the protein (Fig. 1) were prepared by polymerase chain reaction
(PCR). The fragments generated were inserted using EcoRI and Bam-
HI into similarly digested pGEM3Z (Promega).
The plasmids pET4A [16] and p4AIIms [23] encoding the murine
eIF4AI and eIF4AII respectively were used as templates in PCRs to
permit insertion of BamHI^SalI fragments into similarly digested
pGEX-4T (Amersham Pharmacia Biotech) to generate plasmids that
expressed GST^eIF4AI and GST^eIF4AII fusion proteins.
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Modi¢ed forms of the GST^eIF4AI coding sequences containing
single and double mutations were produced using PCR. The changes
made were V144 (GTG) to M144 (ATG) alone or A142 (GCT) to
N142 (AAT) alone or the two changes together within the eIF4AI
coding sequence. The presence of the required mutations in the plas-
mids was veri¢ed by DNA sequencing.
2.2. Transient expression assays
Transient expression assays were performed as described previously
[24]. Brie£y, plasmids (2.5 Wg) were transfected using Lipofectin (Life
Technologies) into BHK cells (35 mm dishes) infected with the re-
combinant vaccinia virus vTF7-3 [25] which expresses T7 RNA poly-
merase. Cell extracts (400:1) were prepared at 20 h post-infection.
Samples were analysed by SDS^PAGE and immunoblotting. Detec-
tion was achieved using horseradish peroxidase-conjugated anti-V5
antibodies (Invitrogen) and chemiluminescence reagents (Pierce).
2.3. Production of BHK cells expressing tagged eIF4AI
BHK-4AI cells that constitutively express the C-terminal V5-tagged
human eIF4AI were prepared by transfection of BHK cells with
pcDNA3.1/GS4AI using Lipofectin and selection of cells using Zeocin
(125 Wg/ml, Invitrogen). BHK-4AI cells were infected with FMDV
O1K as described [12] and harvested at 1^5 h post-infection. The
expression and cleavage of the V5-tagged eIF4AI in BHK-4AI cells
were assessed by immunoblotting as above.
2.4. Expression and puri¢cation of GST^eIF4A fusion proteins
The production of GST fusion proteins in Escherichia coli JM109
was induced with 1 mM isopropyl L-D-thiogalactoside (IPTG). After
cell lysis (by sonication), fusion proteins in phosphate-bu¡ered saline
(PBS) containing 1% Triton X-100 were bound to glutathione-Sephar-
ose (Amersham Pharmacia Biotech), eluted (with 50 mM glutathione
in 50 mM Tris, pH 8.0) and dialysed against PBS containing 20%
glycerol, 1 mM EDTA (pH 8.0) and 1 mM dithithreitol (DTT) (bu¡er
S). In each case, the puri¢ed protein (about 5 mg/l of culture) ap-
peared homogeneous by SDS^PAGE.
2.5. Expression and puri¢cation of recombinant FMDV 3C protease
A XhoI^SalI fragment from pSK3C (derived by KpnI digestion and
religation of pSKRH3C [12] to remove most of the FMDV IRES
sequence) was inserted into the XhoI site of pET28b (Novagen) to
generate pET-FMDV3CXS. This plasmid was transformed into E.
coli BL21(DE3)LysS and recombinant protein expression was induced
with IPTG (1 mM). The His-tagged 3C protease (the hexa-His tag
replaces the normal C-terminal six residues PEPHHE) was bound to
TALON resin (Clontech), eluted with 500 mM imidazole and dialysed
against bu¡er S. The product (about 5 mg/l culture) appeared homo-
geneous by SDS^PAGE and by immunoblotting using anti-His tag
and anti-FMDV 3C antibodies.
2.6. In vitro cleavage of recombinant eIF4A proteins
Puri¢ed GST^eIF4AI (5 Wg) or GST^eIF4AII (5 Wg) was incubated
for 2 h at 37‡C alone or with puri¢ed 3C protease (0.5 Wg) in 100 mM
sodium phosphate bu¡er (pH 7.4), 1 mM EDTA, 1 mM DTT and 5%
glycerol (20 Wl). Reactions were stopped directly by addition of SDS
sample bu¡er or incubated with glutathione-Sepharose beads in PBS/
0.5% Triton X-100 (0.5 ml). The bound proteins were washed and
eluted with SDS sample bu¡er prior to analysis by SDS^PAGE and
immunoblotting using antisera speci¢c for the N- or C-terminus of
eIF4A.
2.7. Antisera against eIF4A
Sheep antisera raised against synthetic peptides derived from the N-
termini of eIF4AI and eIF4AII and a peptide derived from the C-
terminal region common to both proteins were described previously
[26].
2.8. N-Terminal amino acid sequence analysis of eIF4AI cleavage
product
The products generated in vitro by FMDV 3C (as described above)
from 5 Wg of GST^eIF4AI in a 20 Wl reaction were separated by SDS^
PAGE and transferred to polyvinylidene di£uoride membrane. The
blot was stained with GelCode Blue stain reagent (Pierce), the C-
terminal fragment of eIF4AI was excised and subjected to nine cycles
of automated Edman degradation by Dr Nick Morrice of the MRC
Phosphorylation Unit (Dundee, UK). Residues were identi¢ed as their
phenylthiohydantoin derivatives by high-performance liquid chroma-
tography.
3. Results
3.1. eIF4AI is cleaved by FMDV 3C within cells
In our initial studies, it was demonstrated that eIF4A was
cleaved within FMDV-infected cells or when the FMDV 3C
protease was transiently expressed within BHK cells [12]. In
these studies, which used antibodies that do not discriminate
between eIF4AI and eIF4AII, it appeared that cleavage of
eIF4A was incomplete. To analyse the modi¢cation of eIF4AI
individually, an epitope-tagged version of human eIF4AI
(Fig. 1) was introduced into BHK cells and a stable cell line
(BHK-4AI) that expressed this protein was generated (see Fig.
2). Infection of these cells with FMDV resulted in progressive
cleavage of the human eIF4AI and the production of a V5-
tagged 33 kDa species (Fig. 2). This result con¢rmed that the
large cleavage product of eIF4AI contains the C-terminus,
indicating that cleavage occurs within the N-terminal region.
3.2. Characterisation of truncated eIF4AI proteins
A series of N-terminal deletion mutants of eIF4AI was
constructed (see Fig. 1). These each contained a C-terminal
V5-epitope tag and were e⁄ciently expressed in a transient
assay within BHK cells (Fig. 3). Extracts of the FMDV-in-
fected BHK-4AI cells were analysed in parallel (Fig. 3). The
C-terminal cleavage product generated during infection co-
migrated closely with the truncated mutant of eIF4AI lacking
the N-terminal 150 amino acids (v150) which provided a
rough estimate for the location of the cleavage site.
3.3. Identi¢cation of site within eIF4AI cleaved by FMDV 3C
protease
To identify the cleavage site precisely, the GST^eIF4AI and
GST^eIF4AII proteins were incubated with FMDV 3C pro-
tease in vitro. The products were analysed by SDS^PAGE
and immunoblotting (Fig. 4A). A 33 kDa C-terminal product
was generated from GST^eIF4AI but not from the closely
related GST^eIF4AII. The 3C-generated eIF4AI fragment
was isolated and its N-terminal amino acid sequence was de-
termined (VQKLQMEAP). This precisely matches the pub-
lished sequence for eIF4AI residues 144^152 [23]. Thus the
bond cleaved in eIF4AI by FMDV 3C is between E143 and
Fig. 1. Representation of the structure of eIF4AI cDNA and deriva-
tives. The location of the nine conserved motifs (indicated by single
letter amino acid code) present within the eIF4AI sequence (406
amino acids) is indicated. The structures of the truncated derivatives
of eIF4AI are shown. The C-terminal His- and V5-epitope tags are
depicted as ¢lled rectangles.
FEBS 25283 11-10-01 Cyaan Magenta Geel Zwart
W. Li et al./FEBS Letters 507 (2001) 1^52
V144. This result is entirely consistent with the close co-mi-
gration of the C-terminal cleavage product generated in
FMDV-infected cells with the v150 product shown in Fig. 3.
3.4. The N- and C-terminal cleavage products of eIF4AI
dissociate
To be able to interpret the e¡ect of eIF4AI cleavage, it was
important to determine whether the N- and C-terminal cleav-
age products of eIF4AI remained associated. The GST^CPN
fusion product but not the C-terminal cleavage product (CPC)
was bound by glutathione-Sepharose (Fig. 4B,C) indicating
that the two fragments dissociated from one another.
3.5. Analysis of the speci¢city of FMDV 3C for eIF4AI but not
eIF4AII
Although there is a high degree (ca. 90%) of identity be-
tween eIF4AI and eIF4AII, there are di¡erences between
these proteins in the region of the cleavage site identi¢ed in
eIF4AI (Fig. 5A). Substitution of residue V144 for M144
within eIF4AI did not alter its sensitivity to FMDV 3C
(Fig. 5B). Similarly, the A142N mutant remained susceptible
to cleavage by the 3C protease (Fig. 5B). However the double
substitution, A142N and V144M, within the GST^eIF4AI se-
quence rendered it resistant to FMDV 3C cleavage in vitro
(Fig. 5B), consistent with the resistance of GST^eIF4AII to
this protease.
3.6. Mapping the 3C cleavage site within eIF4AI onto the 3D
structure of yeast eIF4A
The 3D structure of yeast eIF4A has been determined [19^
21]. Human/murine eIF4AI is 65% identical to yeast eIF4A
and the presence of several conserved motifs facilitated align-
ment of the yeast and mammalian eIF4A sequences (Fig. 5A).
The cleavage site within human/murine eIF4AI is located be-
tween the GG and TPGR conserved motifs (Fig. 5A) and the
sequence similarity between the yeast and mammalian pro-
teins between these motifs is rather low. We have selected
residues E132/D133 in the yeast sequence to indicate the po-
sition of the scissile bond on the structure of the N-terminal
domain of yeast eIF4A (Fig. 6) as determined [20]. The cleav-
age site is within an exposed, £exible corner of the molecule.
In the ¢rst determination of the structure of the N-terminal
Fig. 2. Cleavage of V5-tagged eIF4AI is induced by FMDV 3C in
cells. BHK-4AI cells, that express the C-terminal V5-tagged human
eIF4AI, were infected with FMDV. At 1, 3 and 5 h post-infection
the cells were lysed and analysed, in parallel with uninfected BHK-
4AI cell extract, by SDS^PAGE and immunoblotting using anti-V5
antibodies. The C-terminal cleavage product (CPC) is indicated.
Fig. 3. Characterisation of the FMDV-induced eIF4AI C-terminal
cleavage product. Extracts from vTF7-3 infected BHK cells that
had been transfected with plasmids encoding the indicated C-termi-
nal V5-tagged forms of eIF4AI were prepared at 20 h post-infec-
tion. Samples were analysed, using anti-V5 antibodies, in parallel
with an extract (labelled FMDV) from FMDV-infected BHK-4AI
cells as in Fig. 2. The positions of the full-length eIF4AI and its C-
terminal cleavage product (CPC) are indicated.
Fig. 4. Direct cleavage of GST^eIF4AI, but not GST^eIF4AII, by FMDV 3C protease results in dissociation of the two fragments. A: GST^
eIF4AI (5 Wg) and GST^eIF4AII (5 Wg) fusion proteins were incubated alone or with FMDV 3C protease (0.5 Wg). Reactions were terminated
and analysed by SDS^PAGE and immunoblotting using an antibody speci¢c for the C-terminus of eIF4A. The full-length fusion protein and
C-terminal cleavage product of eIF4AI are indicated. B and C: Puri¢ed GST^eIF4AI was incubated alone or with FMDV 3C protease as indi-
cated (as for A). Samples were analysed directly or after incubation with glutathione-Sepharose (GSH-Seph) beads. The bound proteins were
analysed in parallel with the initial reaction products by SDS^PAGE and immunoblotting using antisera speci¢c for the C-terminus (B) or the
N-terminus (C) of eIF4AI. The eIF4AI C-terminal cleavage product (CPC) and the GST^CPN fusion protein are indicated.
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yeast eIF4A [19], this portion of the molecule (residues 125^
134) was not visible and was considered disordered.
4. Discussion
The FMDV 3C protease cleaves the viral polyprotein at
several positions. The most common amino acid pair cleaved
by FMDV 3C is E/G (glutamate/glycine) but E/S, Q/L, Q/I
and Q/T pairs are also cut. This contrasts with the predom-
inant use of Q/G (glutamine/glycine) cleavage sites by the
enterovirus (e.g. PV) and cardiovirus (e.g. EMCV) 3C pro-
teases. This di¡erence in speci¢city is consistent with the abil-
ity of just the FMDV 3C protease to cleave the E143/V144
bond within eIF4AI. The cleavage of eIF4AI but not eIF4AII
by FMDV 3C was surprising in view of the high degree of
identity between the two proteins. However, co-expression of
the FMDV 3C with tagged eIF4AI or tagged eIF4AII within
mammalian cells also provided evidence for cleavage of eI-
F4AI but not of eI4FAII by this protease (data not shown).
Furthermore, we have shown that two amino acid di¡erences
between eIF4AI and eIF4AII in the vicinity of the cleavage
site are su⁄cient to account for this speci¢city. The modi¢ca-
tion of residue V144 to M alone did not render eIF4AI resis-
tant to cleavage even though this residue is adjacent to the
scissile bond. Similarly, the substitution of residue A142 by N
alone did not block cleavage, but the presence of both mod-
i¢cations together, as in eIF4AII, conferred resistance to the
protease.
Cleavage of eIF4AI by FMDV 3C resulted in dissociation
of the N-terminal and C-terminal fragments (Fig. 4). Thus the
cleavage separates three of the nine conserved regions that are
found in all members of the DEAD box family of proteins
(see [2] and Fig. 1). Modi¢cation of the ATPase A motif alone
blocks ATP binding and the helicase activity of eIF4A. Sim-
ilarly, modi¢cation of the conserved GG and TPGR motifs,
adjacent to the cleavage site, also blocks ATPase activity [17].
Thus the truncated C-terminal fragment of eIF4AI lacks crit-
ical features of the eIF4A molecule and is accordingly ex-
pected to be inactive as a helicase.
The cleavage of eIF4AI within FMDV-infected cells does
not go to completion but it should be noted that eIF4A is the
most abundant of the translation initiation factors [14]. The
progressive cleavage of eIF4AI co-incides with the decrease in
the level of viral RNA translation that occurs in FMDV-in-
fected cells [12]. However, it is unclear whether the decrease in
viral protein synthesis is entirely attributable to the loss of
eIF4AI. Indeed, since we can also observe decay in the pri-
mary cleavage products of eIF4GI (G.J.B. and N.R.-S., un-
published results and [12]), it is likely that several di¡erent
processes contribute towards this e¡ect.
The conservation of sequences between the mammalian and
yeast eIF4A proteins allowed us to locate the FMDV 3C
cleavage site on the known 3D structure of yeast eIF4A
[20]. The £exible and exposed location of the cleavage site
may explain the susceptibility of this region to the protease.
Fig. 5. Two amino acid substitutions in GST^eIF4AI confer resis-
tance to cleavage by FMDV 3C protease in vitro. A: Sequence
comparison of human/murine eIF4AI and eIF4AII with yeast
eIF4A between the conserved GG and TPGR sequence motifs (n.b.
for both eIF4AI and eIF4AII the human and murine amino acid se-
quences are the same). Residues that are identical in the di¡erent se-
quences are boxed and shaded. The location of the scissile bond in
eIF4AI is indicated. Selected residues in eIF4AI and yeast eIF4A
are numbered. B: The wild-type and mutant GST^eIF4AI fusion
proteins (with single or double amino acid substitutions) were incu-
bated alone or with FMDV 3C protease in vitro and analysed as in
Fig. 4A. The C-terminal cleavage product (CPC) is indicated.
Fig. 6. Localisation of the cleavage site in eIF4AI recognised by
FMDV 3C protease on the 3D structure. The 3D structure of the
N-terminal region (residues 1^223) of yeast eIF4A as determined by
X-ray crystallography [20] is shown. The structure is colour-coded
according to the b-value. The red regions are most £exible while the
blue regions are least mobile. Residues E132 and D133 correspond-
ing to the cleavage site are indicated by the presence of the side
chains.
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The peptide bond cleaved by FMDV 3C may be within a
region that can associate with other molecules, e.g. eIF4G or
eIF4B. If so, the partial cleavage of eIF4A observed in
FMDV-infected cells may re£ect modi¢cation of only the frac-
tion of eIF4A that is not complexed with other proteins.
Clearly the cleavage of one population of eIF4AI molecules
may have signi¢cant e¡ects if each population has distinct
functional roles. Even if this is not the case, the partial cleav-
age of eIF4A by FMDV 3C may modify the amount of eIF4A
associated with eIF4G or eIF4B and hence a¡ect their activity.
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